Under the terms of the agreement, the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes for Health (NIH), will fund and conduct a preclinical anti-microbial evaluation of Viprovex for potential use as a possible treatment for certain infectious respiratory diseases including influenza, measles and severe acute respiratory syndrome (SARS).
The NIAID offers both in vitro and animal model evaluation services to help facilitate the rapid development and commercialization of products for the treatment of infectious diseases. The evaluation will be conducted through NIAID contracted testing laboratories.
Viprovex is the trade name used in referring to formulations of Homspera for potential indications for treatment of maladies caused by exposure to various chemical and biological agents. Homspera is a generic name used by ImmuneRegen to describe the synthetic peptide Sar9, Met (O2)11-Substance P.